Nothing Special   »   [go: up one dir, main page]

EA201591888A1 - Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов - Google Patents

Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов

Info

Publication number
EA201591888A1
EA201591888A1 EA201591888A EA201591888A EA201591888A1 EA 201591888 A1 EA201591888 A1 EA 201591888A1 EA 201591888 A EA201591888 A EA 201591888A EA 201591888 A EA201591888 A EA 201591888A EA 201591888 A1 EA201591888 A1 EA 201591888A1
Authority
EA
Eurasian Patent Office
Prior art keywords
replication
vaccines
flaviviruss
defect
vaccine vectors
Prior art date
Application number
EA201591888A
Other languages
English (en)
Inventor
Константин В. Пугачев
Александр А. Румянцев
Мэриэнн Гил-Молони
Харольд Клеантус
Original Assignee
Санофи Пастер Байолоджикс Ко.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи Пастер Байолоджикс Ко. filed Critical Санофи Пастер Байолоджикс Ко.
Publication of EA201591888A1 publication Critical patent/EA201591888A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к репликационно-дефектным вакцинам и вакцинным векторам против флавивирусов, а также к соответствующим композициям и методам.
EA201591888A 2008-03-14 2009-03-16 Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов EA201591888A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6945108P 2008-03-14 2008-03-14
US9281408P 2008-08-29 2008-08-29

Publications (1)

Publication Number Publication Date
EA201591888A1 true EA201591888A1 (ru) 2016-05-31

Family

ID=41065743

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201001491A EA023888B1 (ru) 2008-03-14 2009-03-16 Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
EA201591888A EA201591888A1 (ru) 2008-03-14 2009-03-16 Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201001491A EA023888B1 (ru) 2008-03-14 2009-03-16 Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов

Country Status (16)

Country Link
US (2) US8815564B2 (ru)
EP (1) EP2265284A4 (ru)
JP (1) JP5779352B2 (ru)
KR (1) KR101719316B1 (ru)
CN (2) CN102202687B (ru)
AU (1) AU2009223727B2 (ru)
BR (1) BRPI0908936A2 (ru)
CA (1) CA2717499A1 (ru)
EA (2) EA023888B1 (ru)
HK (1) HK1162306A1 (ru)
IL (1) IL208147A (ru)
MX (1) MX2010010034A (ru)
SG (1) SG188891A1 (ru)
UA (1) UA103316C2 (ru)
WO (1) WO2009114207A2 (ru)
ZA (1) ZA201006437B (ru)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008100290A2 (en) * 2006-09-29 2008-08-21 Sanofi Pasteur Biologics Co Recombinant rhinovirus vectors
EP2155782A2 (en) 2007-03-26 2010-02-24 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP3023436A1 (en) 2007-07-03 2016-05-25 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
AU2009223727B2 (en) * 2008-03-14 2014-09-11 Sanofi Pasteur Biologics, Llc Replication-defective flavivirus vaccines and vaccine vectors
AU2009229165A1 (en) * 2008-03-27 2009-10-01 Sanofi Pasteur Biologics Co. Recombinant rhinovirus vectors
US10722562B2 (en) 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
CA2755257A1 (en) * 2009-03-16 2010-09-23 Sanofi Pasteur Biologics Co. Replication-defective flavivirus vaccine vectors against respiratory syncytial virus
SG177402A1 (en) * 2009-06-29 2012-02-28 Genocea Biosciences Inc Vaccines and compositions against streptococcus pneumoniae
BRPI0914507A2 (pt) * 2009-12-23 2012-04-10 Fundacao Oswaldo Cruz vacina para lentivìrus baseada em vìrus recombinante vacinal da febre amarela
WO2011119628A2 (en) 2010-03-23 2011-09-29 The Regents Of The University Of California Compositions and methods for self-adjuvanting vaccines against microbes and tumors
EP2550292B1 (en) * 2010-03-24 2017-11-22 Research Development Foundation Flavivirus host range mutations and uses thereof
US8889148B2 (en) 2010-07-01 2014-11-18 Research Development Foundation Flavivirus host-range mutations and uses thereof
SG192060A1 (en) 2011-01-20 2013-08-30 Genocea Biosciences Inc Vaccines and compositions against streptococcus pneumoniae
CN102181408A (zh) * 2011-01-30 2011-09-14 中国检验检疫科学研究院 圣路易斯脑炎病毒样颗粒的制备方法及其应用
CA2836501A1 (en) 2011-07-12 2013-01-17 Gwong-Jen J. Chang Identification of a west nile virus cd4 t cell epitope and use thereof
US20150030565A1 (en) * 2012-01-09 2015-01-29 Sanofi Pasteur Biologics, Llc Purification of flaviviruses
WO2013116770A1 (en) * 2012-02-01 2013-08-08 Sanofi Pasteur Biologics, Llc Replication-defective flavivirus vaccines and vaccine vectors
WO2013138670A1 (en) * 2012-03-15 2013-09-19 Icahn School Of Medicine At Mount Sinai Yellow fever virus ns5 mutants as flavivirus vaccine candidates
WO2013138776A1 (en) * 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
US8895028B2 (en) * 2012-07-20 2014-11-25 Arbovax, Inc. Methods and compositions for dengue virus 3 (DV3) infectious clone
US20140271708A1 (en) * 2013-03-15 2014-09-18 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies G
MX369776B (es) * 2014-03-01 2019-11-21 Univ Texas Vectores recombinantes del virus isfahan.
AU2015276929B2 (en) * 2014-06-20 2021-04-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric West Nile/Dengue viruses and methods of use
EP3031923A1 (en) * 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
WO2016193370A1 (en) 2015-06-02 2016-12-08 De Staat Der Nederlanden, Vert. Door De Minister Van Vws, Ministerie Van Volksgezondheid, Welzijn En Sport Surface display of antigens on gram-negative outer membrane vesicles
WO2018060771A1 (en) 2016-09-30 2018-04-05 Sanofi Pasteur Live attenuated chimeric zika virus and its use as an immunogenic composition
CA3057171A1 (en) 2017-03-30 2018-10-04 The University Of Queensland Chimeric polypeptides containing virus fusion ectodomain and complementary heptad repeats and uses thereof
CA3067164A1 (en) * 2017-06-12 2018-12-20 Washington University Zika virus strains for treatment of glioblastoma
EP4400174A3 (en) 2017-09-01 2024-10-23 The Francis Crick Institute Limited Immunoregulatory molecules and uses therefor
GB201716254D0 (en) * 2017-10-05 2017-11-22 Univ Leuven Kath Live-attenuated flaviruses with heterologous antigens
GB201814563D0 (en) * 2018-09-07 2018-10-24 Univ Leuven Kath Chimeric flavivirus lyssavirus vaccines
CN109943590B (zh) * 2019-04-18 2022-11-18 西南大学 一种复制缺陷型猪圆环病毒、其制备方法及应用
CN110157685B (zh) * 2019-05-20 2022-11-01 中国科学院武汉病毒研究所 一种复制缺陷西尼罗病毒的制备方法及应用
SG11202100677VA (en) * 2019-05-28 2021-02-25 Chiang Mai Univ Mature virus-like particles of flaviviruses
EP4041301A1 (en) * 2019-09-13 2022-08-17 Katholieke Universiteit Leuven Chimeric filovirus vaccines

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393201A (en) 1981-11-04 1983-07-12 The Wistar Institute DNA Which codes for glycoprotein of era-strain rabies virus
JPS6011428A (ja) 1983-02-01 1985-01-21 ジエネンテク，インコ−ポレイテツド 狂犬病ワクチン
US5830477A (en) * 1984-04-25 1998-11-03 Transgene S.A. Vaccine against rabies and process for preparation thereof
FR2563434B1 (fr) * 1984-04-25 1986-07-25 Transgene Sa Vaccin contre la rage et procede pour sa preparation
US5274087A (en) 1986-08-13 1993-12-28 Molecular Diagnostics, Inc. cDNA coding for carcinoembryonic antigen (CEA)
ATE96168T1 (de) 1986-08-13 1993-11-15 Miles Inc Karzinoembryonisches antigen kodierende cdns.
US5122599A (en) 1986-08-13 1992-06-16 Molecular Diagnostics, Inc. CDNAS coding for members of the carcinoembryonic antigen family
IL89102A0 (en) 1988-01-29 1989-08-15 Lilly Co Eli Vectors,compounds and methods for expression of a human adenocarcinoma antigen
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US6184024B1 (en) 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
JPH03139286A (ja) * 1989-10-25 1991-06-13 Nippon Seibutsu Kagaku Kenkyusho 狂犬病ウイルスｇ蛋白質を産生する組み換えバキュロウイルス及びｇ蛋白質の製造方法
US6071716A (en) 1990-10-01 2000-06-06 Dana-Farber Cancer Institute DNA encoding, B7, a new member of the IG superfamily with unique expression on activated and neoplastic B cells
ATE247163T1 (de) 1991-03-07 2003-08-15 Virogenetics Corp Gentechnologisch hergestellter stamm für impfstoffe
ATE248924T1 (de) 1991-05-06 2003-09-15 Us Gov Health & Human Serv Karcinoembryonale antigen expremierende rekombinante viren und methoden ihrer anwendung
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5830753A (en) 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US6045802A (en) 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
ES2154738T3 (es) 1994-10-03 2001-04-16 Us Gov Health & Human Serv Composicion que comprende un virus recombinante que expresa un antigeno y un virus recombinante que expresa una molecula inmunoestimuladora.
US5939526A (en) 1995-03-21 1999-08-17 Ludwig Institute For Cancer Research Isolated RAGE-1 derived peptides which complex with HLA-B7 molecules and uses thereof
US6083925A (en) * 1995-06-07 2000-07-04 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
KR100517323B1 (ko) * 1997-02-28 2005-09-27 아캠비스 인코포레이티드 키메라 플라비바이러스 백신
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
US20040005542A1 (en) * 2001-06-22 2004-01-08 Krempl Christine D Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes
DE69837273T2 (de) 1997-10-08 2008-01-31 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Menschliches krebsantigen ny eso-1/cag-3 und dazu kodierendes gen
NZ504725A (en) 1997-11-28 2003-02-28 Crown In The Right Of The Quee Flavivirus expression and delivery system
AU772547B2 (en) 1998-08-31 2004-04-29 Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin, The Polypeptides and polynucleotides from coagulase-negative staphylococci
AU4903101A (en) 1999-11-30 2001-07-09 Cornell Research Foundation Inc. Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
WO2001040469A2 (en) * 1999-12-03 2001-06-07 Yale University Tick antigens and compositions and methods comprising them
GB2372991B (en) * 2001-03-09 2004-11-17 Fiocruz Fundacao Oswaldo Cruz Flavivirus expression vector
WO2002072803A2 (en) * 2001-03-09 2002-09-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Subgenomic replicons of the flavivirus dengue
KR100921592B1 (ko) * 2001-06-01 2009-10-14 사노피 파스테르 바이오로직스 씨오 키메라 플라비바이러스 벡터
NZ533237A (en) * 2001-11-26 2005-11-25 Univ Queensland Flavivirus vaccine delivery system
CN1829796B (zh) * 2002-10-09 2010-05-26 Cid株式会社 新的日本脑炎病毒的全长基因组RNA、来自它的感染性的JEV cDNA及其应用
CN1322120C (zh) * 2003-03-20 2007-06-20 上海天甲生物医药有限公司 乙肝乙脑双价疫苗
AU2003902842A0 (en) 2003-06-06 2003-06-26 The University Of Queensland Flavivirus replicon packaging system
CN1304579C (zh) * 2003-07-21 2007-03-14 上海天甲生物医药有限公司 重组的以黄热病病毒为载体的疫苗
US7473531B1 (en) 2003-08-08 2009-01-06 Colora Corporation Pancreatic cancer targets and uses thereof
US8287878B2 (en) * 2004-04-09 2012-10-16 Wyeth Llc Synergistic attenuation of vesicular stomatitis virus, vectors thereof and immunogenic compositions thereof
CN1972958B (zh) * 2004-04-12 2013-01-23 美国政府卫生与公共服务部 应用腺病毒载体诱导免疫应答的方法
CN101018860B (zh) * 2004-07-12 2013-02-27 美国天甲生物医药有限公司 黄病毒疫苗
US7332322B2 (en) 2004-09-14 2008-02-19 Ilya Frolov Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof
CA2597655A1 (en) * 2005-02-16 2006-08-24 The Council Of The Queensland Institute Of Medical Research Flavivirus replicon constructs for tumour therapy
BRPI0609949A2 (pt) * 2005-04-24 2010-05-11 Acambis Inc flavivìrus recombinante, seu uso na preparação de vacina, composição farmacêutica compreendendo o mesmo, molécula de ácido nucléico e método para atenuar candidato a vacina de flavivìrus
KR101499750B1 (ko) * 2006-02-27 2015-03-06 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 가감염성 플라비바이러스 및 이들의 용도
BRPI0714721A2 (pt) 2006-07-14 2013-04-24 Sanofi Pasteur Biologics Co construÇço de vacinas de vÍrus recombinante por inserÇço direta mediada por transpàson de determinantes imunolàgicos estranhos em proteÍnas de vÍrus vetorial
US8486417B2 (en) 2007-01-31 2013-07-16 Sanofi Pasteur Biologics, Llc Recombinant bicistronic Flavivirus vectors
US8591916B2 (en) 2007-01-31 2013-11-26 Sanofi Pasteur Biologics, Llc Flavivirus vaccine vector against influenza virus
EP2117588A4 (en) 2007-02-09 2011-05-04 Sanofi Pasteur Biologics Co VIRAL VECTORS AND METHODS OF USE
WO2008137163A1 (en) 2007-05-07 2008-11-13 The Board Of Regents Of The University Of Texas System Two-component genome flavivirus and uses thereof
AU2009223727B2 (en) 2008-03-14 2014-09-11 Sanofi Pasteur Biologics, Llc Replication-defective flavivirus vaccines and vaccine vectors
CA2755257A1 (en) 2009-03-16 2010-09-23 Sanofi Pasteur Biologics Co. Replication-defective flavivirus vaccine vectors against respiratory syncytial virus

Also Published As

Publication number Publication date
KR20110002845A (ko) 2011-01-10
CA2717499A1 (en) 2009-09-17
UA103316C2 (ru) 2013-10-10
EP2265284A4 (en) 2012-04-25
IL208147A (en) 2016-02-29
AU2009223727A1 (en) 2009-09-17
US20110135686A1 (en) 2011-06-09
SG188891A1 (en) 2013-04-30
MX2010010034A (es) 2010-12-06
JP2011516040A (ja) 2011-05-26
ZA201006437B (en) 2016-03-30
CN102202687A (zh) 2011-09-28
WO2009114207A2 (en) 2009-09-17
JP5779352B2 (ja) 2015-09-16
AU2009223727B2 (en) 2014-09-11
KR101719316B1 (ko) 2017-03-24
EP2265284A2 (en) 2010-12-29
WO2009114207A3 (en) 2010-01-07
EA023888B1 (ru) 2016-07-29
US8815564B2 (en) 2014-08-26
CN102202687B (zh) 2015-07-29
IL208147A0 (en) 2010-12-30
US9217158B2 (en) 2015-12-22
CN105039266A (zh) 2015-11-11
HK1162306A1 (en) 2012-08-31
BRPI0908936A2 (pt) 2017-03-28
US20130243812A1 (en) 2013-09-19
EA201001491A1 (ru) 2011-06-30

Similar Documents

Publication Publication Date Title
EA201591888A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
NO20090194L (no) Rekombinant viral vaksine
CY1119284T1 (el) ΣΩΜΑΤΙΔΙΑ ΠΑΡΟΜΟΙΑ ΜΕ ΙΟ ΓΛΥΚΟ-ΠΡΩΤΕΪΝΗΣ ΛΥΣΣΑΣ (VLPs)
MX352324B (es) Vacunas multivalentes de nanovehiculos sinteticos.
EA202190619A1 (ru) Противовирусные соединения
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
EA201001820A1 (ru) Новые иммуноадъювантные соединения на основе флагеллина и их применение
EA201190259A1 (ru) Противовирусные соединения
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
EA201490596A1 (ru) Новые производные дигидрохинолин-2-она
EA201492223A1 (ru) Новые диазаспироциклоалканы и азаспироциклоалканы
EA201391515A1 (ru) Инактивированная вакцина вируса денге
EA201170396A1 (ru) 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
EA201590705A1 (ru) ПОЛУЧЕНИЕ РЕКОМБИНАНТНОЙ ВАКЦИНЫ В E.coli ПОСРЕДСТВОМ ЭНЗИМАТИЧЕСКОЙ КОНЪЮГАЦИИ
EA201070271A1 (ru) Пептиды для получения вакцины
EA201490567A1 (ru) Новые бициклические производные дигидрохинолин-2-она
EA201492002A1 (ru) Противовирусные соединения
EA201490846A1 (ru) Новые производные арилхинолина
EA201100268A1 (ru) Вакцина
MX2013004159A (es) Proteina vp6 de la capside de norovirus y de rotavirus para el uso como vacuna combinada.
MX338898B (es) Vacuna contra el virus del dengue inactivado con un adyuvante libre de aluminio.
EA201070853A1 (ru) Кристаллический (r)-2-(4-циклопропансульфонилфенил)-n-пиразин-2-ил-3-(тетрагидропиран-4-ил)пропионамид
EA201290642A1 (ru) Соединения и способы
EA201070009A1 (ru) Производные 7-алкинил-1,8-нафтиридонов, их получение и их применение в терапии
EA201170533A1 (ru) Высокодиспергируемый диоксид кремния для резин и способ его получения